Senti Biosciences (SNTI) TD Cowen 46th Annual Health Care Conference summary
Event summary combining transcript, slides, and related documents.
TD Cowen 46th Annual Health Care Conference summary
3 Mar, 2026Key technology and therapeutic approach
Logic-gated cell therapies selectively kill cancer cells while sparing healthy cells, addressing a major challenge in oncology treatment.
SENTI-202 is an off-the-shelf allogeneic NK cell therapy targeting CD33 and FLT3, covering over 95% of AML patients.
The therapy uses an activating CAR for cancer targets, an inhibitory CAR for healthy cells, and IL-15 to enhance NK activity.
Logic-gating technology is adaptable to both NK and T cells and is being explored for solid tumors.
SENTI-202 is not genetically restricted, allowing broad patient eligibility.
Clinical data and outcomes
In a phase I study with relapsed/refractory AML patients, SENTI-202 achieved a 50% overall response rate and 42% CR/CRh at RP2D, with a 7.6-month median duration of CRs.
100% of CRs were MRD negative, indicating deep responses and potential for improved patient outcomes.
The safety profile was favorable, with most adverse events related to lymphodepletion and manageable; no significant CRS observed.
Responses were observed across patients with adverse genetic features and those refractory to prior therapies.
Outpatient dosing is feasible, and the product is suitable for rapid delivery due to its off-the-shelf nature.
Mechanism of action and differentiation
SENTI-202's logic gate design enables selective killing of AML blasts and leukemic stem cells while sparing healthy hematopoietic stem cells.
CyTOF analysis confirmed maintenance or increase of healthy stem cells in responders, supporting the logic gate's function.
The therapy is effective even in patients with high-risk genetics, including complex karyotypes.
The approach is differentiated from existing therapies by not requiring specific genetic mutations and by targeting both AML blasts and stem cells.
The technology is being adapted for solid tumors, with proof-of-concept shown for CEA-positive cancers using a NOT gate to protect healthy cells.
Latest events from Senti Biosciences
- Shareholders will vote on a merger offering milestone-based CVRs, not cash, for their shares.SNTI
Proxy filing21 Jul 2026 - Majority of shares registered for resale could shift control and cause significant dilution.SNTI
Registration filing16 Jul 2026 - Shareholders to receive milestone-based CVRs as core assets are spun off in a strategic merger.SNTI
Proxy filing15 Jul 2026 - SENTI-202 demonstrates durable, MRD-negative responses in AML using innovative logic gating technology.SNTI
The Citizens JMP Life Sciences Conference 20259 Jul 2026 - Highly dilutive resale of 15.97M shares may shift control and pressure stock price.SNTI
Registration filing18 Jun 2026 - Q1 2026 saw SENTI-202 clinical progress, narrowed net loss, and new $40M financing.SNTI
Q1 202614 May 2026 - SENTI-202 achieved 50% ORR and 42% CR/CRh with excellent safety in R/R AML Phase 1 trial.SNTI
Corporate presentation9 Apr 2026 - Positive SENTI-202 clinical progress, RMAT status, and $61.4M net loss with $16.4M cash.SNTI
Q4 202527 Mar 2026 - SENTI-202 achieved 42% CR/CRh in AML with strong safety and rapid recovery, advancing to pivotal trials.SNTI
Leerink Global Healthcare Conference 20269 Mar 2026